Publications · 2020
Therapies Offered at Residential Addiction Treatment Programs in the US
JAMA , 2020 · doi:10.1001/jama.2020.8969
Overview
Using simulated-patient calls to a random sample of US residential addiction facilities, this research letter examines which evidence-based treatments, such as buprenorphine-naloxone and nonpharmacologic therapies including CBT, are available for opioid use disorder, and how availability differs between for-profit and nonprofit centers.
Abstract
This study uses simulated patient calls to a random sample of US residential addiction treatment facilities to investigate the availability of opioid agonist treatment (buprenorphine-naloxone) and nonpharmacologic therapies (eg, CBT) for opioid use disorder, and differences by for-profit vs nonprofit center status.
Recognition & impact
Awards1
- Highest Impact Publications (2020-2021)American Society of Addiction Medicine
Cited in policy & guidance6
- 42 CFR 8 Medications for the Treatment of Opioid Use DisorderHHS Proposed Rule (incorporates elimination of DATA Waiver Program)
- Major Gaps in the Cascade of Care for Opioid Use Disorder Implications for Clinical PracticeLeadership commentary from CDC, SAMHSA, and NIDA
- Closing Gaps in the Care Continuum: Opportunities to Improve Substance Use Disorder Care in the Federal Health ProgramsExpert Testimony, US Senate Finance Subcommittee on Health Care
- Treating Opioid Use Disorder in General Medical SettingsMedical textbook
- Long-Term Treatment of Opioid Use Disorder with MedicationsThe Oxford Handbook of Opioids and Opioid Use Disorder
- The Opioid Epidemic: Origins, Current State and Potential SolutionsTextbook for college courses on psychology, human behavior, and related fields
Media11
- Most residential addiction treatment programs don’t offer live-saving medicationNPR (WBUR)
- ExclusivesMedPage Today Feature Story
- Treatment programs lack standard care opioid addictionAxios
- The opioid epidemic is surging among Black people because of unequal access to treatmentScientific American
- Federal embeds take on homelessnessPolitico
- We have treatments for opioid addiction that work. So why is the problem getting worse?Vox
- $11M for North Carolina work-based rehab raises concernsKFF Health News
- A $30 million gift to build an addiction treatment center. Then staffers had to run it.KFF Health News
- Addiction harm reductionNew York Times
- Faith healing should not be mainstream treatment for addictionNew York Times
- We need more meds, not beds, to help people recovering from addictionScientific American
Topics
- residential addiction treatment
- MOUD
- buprenorphine
- evidence-based treatment
- for-profit care
- audit study
- treatment quality
- DATA Waiver
How to cite
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett M. Therapies Offered at Residential Addiction Treatment Programs in the US. JAMA; 2020. doi:10.1001/jama.2020.8969
Show BibTeX
@article{beetham2020therapiesoffered,
title = {{Therapies Offered at Residential Addiction Treatment Programs in the US}},
author = {Beetham, T. and Saloner, B. and Gaye, M. and Wakeman, S. E. and Frank, R. G. and Barnett, M.},
journal = {JAMA},
year = {2020},
doi = {10.1001/jama.2020.8969},
url = {https://doi.org/10.1001/jama.2020.8969},
abstract = {This study uses simulated patient calls to a random sample of US residential addiction treatment facilities to investigate the availability of opioid agonist treatment (buprenorphine-naloxone) and nonpharmacologic therapies (eg, CBT) for opioid use disorder, and differences by for-profit vs nonprofit center status.},
keywords = {residential addiction treatment; MOUD; buprenorphine; evidence-based treatment; for-profit care; audit study; treatment quality; DATA Waiver},
note = {Awards: Highest Impact Publications (2020-2021), American Society of Addiction Medicine. Media coverage: NPR (WBUR), MedPage Today Feature Story, Axios, Scientific American}
}